Biomarker Concentrations at 1‐Month Follow‐Up and Long‐Term Changes Over Time
chronic kidney disease, nonobstructive coronary arteries, obstructive coronary artery disease, dyslipidemia, heart failure, diabetes
MYOCARDIAL INFARCTION, ISCHEMIC STROKE, PERIPHERAL VASCULAR DISEASE, DYSLIPIDEMIA, REGRESSION, HEART FAILURE, HYPERTENSION, DIABETES
One‐month biomarker concentrations in the follow‐up cohort are given in Table Biomarker Concentrations and Multiple Linear Regression Results in the Follow‐Up Cohort at 1 Month After the MIInflammationOxidative stressHypoxiaBiomarker data presented as medians (with interquartile ranges). Model 1: adjusted for randomized treatment (clopidogrel vs ticagrelor) and corresponding biomarker concentration at baseline. Model 2: additionally adjusted for baseline clinical characteristics (age, sex, body mass index, current smoking, hypertension, dyslipidemia [medical history and/or lipid treatment at admission], diabetes, chronic kidney disease [medical history], MI type [ST‐segment–elevation MI/non–ST‐segment–elevation MI], previous MI, previous ischemic stroke, previous heart failure, peripheral vascular disease, and revascularization during index hospitalization). GDF‐15 indicates growth differentiation factor 15; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐cTnT, high‐sensitivity cardiac troponin T; MI, myocardial infarction; MI‐CAD, MI with obstructive coronary artery disease; MINOCA, MI with nonobstructive coronary arteries; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.Statistically significant values.